Drugs / Autologous anti-CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07523542 | Mar 2026 → Mar 2027 expected | lupus nephritis, systemic lupus erythematosus | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous anti-CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07523542 ↗ |
| Action | Deplete | “CD19-directed CAR-T can produce profound B-cell depletion” NCT07523542 ↗ |
| Modality | Cell therapy | “Autologous anti-CD19 CAR-T cells are patient-derived T lymphocytes” NCT07523542 ↗ |
| Route | Intravenous | “a single intravenous infusion is administered” NCT07523542 ↗ |
| Target | CD19 | “genetically engineered to target CD19-expressing B cells” NCT07523542 ↗ |